| Lymphoma, Non-Hodgkin

Rayos vs Ruxience

Side-by-side clinical, coverage, and cost comparison for lymphoma, non-hodgkin.

Deep comparison between: Rayos vs Ruxience with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsRuxience has a higher rate of injection site reactions vs Rayos based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Ruxience but not Rayos, including UnitedHealthcare

Category

Rayos

Ruxience

At A Glance

RouteOral

FrequencyDaily

ClassCorticosteroid

RouteIV infusion

ClassCD20-directed cytolytic antibody

Indications

Dermatitis, Atopic
Allergic rhinitis (disorder)
Serum Sickness
Dermatitis Herpetiformis
Contact Dermatitis
Exfoliative dermatitis
Mycosis Fungoides
Pemphigus
Erythema Multiforme
Congenital Adrenal Hyperplasia
Hypercalcemia
thyroiditis; nonsuppurative
Adrenal gland hypofunction
Crohn Disease
Ulcerative Colitis
Autoimmune hemolytic anemia
Anemia, Diamond-Blackfan
Immune thrombocytopenic purpura
Pure Red-Cell Aplasia
Acute leukemia
Lymphoma, Non-Hodgkin
Multiple Sclerosis
Cerebral Edema
Ophthalmia, Sympathetic
Uveitis
Chronic Obstructive Airway Disease
Aspergillosis, Allergic Bronchopulmonary
Aspiration pneumonitis
Asthma
Tuberculosis
Extrinsic allergic alveolitis
Bronchiolitis Obliterans Organizing Pneumonia
Idiopathic eosinophilic pneumonitis
Idiopathic Pulmonary Fibrosis
Pneumonia, Lipid
Sarcoidosis
Nephrotic Syndrome
Primary gout
Ankylosing spondylitis
Dermatomyositis
Polymyalgia Rheumatica
Arthritis, Psoriatic
Polychondritis, Relapsing
Rheumatoid Arthritis
Sjogren's Syndrome
Lupus Erythematosus, Systemic
Vasculitis
Trichinellosis
Tuberculosis, Meningeal

Lymphoma, Non-Hodgkin
Chronic Lymphocytic Leukemia
Rheumatoid Arthritis
Granulomatosis with polyangiitis
Microscopic Polyarteritis
Pemphigus Vulgaris

Dosing

All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.

Lymphoma, Non-Hodgkin 375 mg/m2 IV; once weekly for 4 or 8 doses (relapsed/refractory), on Day 1 of each chemotherapy cycle for up to 8 doses (previously untreated follicular or DLBCL), or every 8 weeks for 12 doses as single-agent maintenance.

Chronic Lymphocytic Leukemia 375 mg/m2 IV on Day 1 of Cycle 1, then 500 mg/m2 IV on Day 1 of Cycles 2-6 in combination with fludarabine and cyclophosphamide, every 28 days.

Rheumatoid Arthritis Two 1,000 mg IV infusions separated by 2 weeks (one course) every 24 weeks or based on clinical evaluation, but not sooner than every 16 weeks, in combination with methotrexate.

Granulomatosis with polyangiitis, Microscopic Polyarteritis Induction: 375 mg/m2 IV once weekly for 4 weeks; follow-up: two 500 mg IV infusions separated by 2 weeks, then 500 mg IV every 6 months based on clinical evaluation, in combination with glucocorticoids.

Pemphigus Vulgaris Two 1,000 mg IV infusions separated by 2 weeks plus tapering glucocorticoids; maintenance: 500 mg IV at Month 12 and every 6 months thereafter; relapse: 1,000 mg IV, no sooner than 16 weeks after the previous infusion.

Contraindications

Known hypersensitivity to prednisone or any excipient

—

Drug Interactions

1287View drug interactions

538View drug interactions

Adverse Reactions

Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain

Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure

Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone

Most common (>=25%) Infusion-related reactions, fever, lymphopenia, chills, infection, asthenia (NHL); infusion-related reactions, neutropenia (CLL).

Serious Infusion-related reactions, severe mucocutaneous reactions, hepatitis B reactivation with fulminant hepatitis, progressive multifocal leukoencephalopathy, tumor lysis syndrome, infections, cardiovascular adverse reactions, renal toxicity, bowel obstruction and perforation.

Postmarketing Prolonged pancytopenia, marrow hypoplasia, late-onset neutropenia, fatal cardiac failure, uveitis, optic neuritis, systemic vasculitis, pleuritis, lupus-like syndrome, serum sickness, polyarticular arthritis, vasculitis with rash, viral infections including PML, Kaposi's sarcoma progression, severe mucocutaneous reactions, pyoderma gangrenosum, bowel obstruction and perforation, fatal bronchiolitis obliterans, fatal interstitial lung disease, PRES/RPLS.

Pharmacology

Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.

Rituximab-pvvr is a chimeric monoclonal antibody that targets the CD20 antigen on pre-B and mature B-lymphocytes, mediating B-cell lysis through complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC).

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Rayos